Table I.
Distribution of clinical factors and risk score values by lymphoma subtype. Hazard Ratios and c-statistics calculated for Overall Survival. P values for individual factors can be found in the supplementary material.
| AITL | PTCL NOS | ALK-ALCL | |||||
|---|---|---|---|---|---|---|---|
| N (%) | HR (95% CI) | N (%) | HR (95% CI) | N (%) | HR (95% CI) | ||
| Individual Prognostic Factors | 145 | 306 | 152 | ||||
| Gender | Male | 64 (44) | 1.00 | 115 (38) | 1.00 | 45 (30) | 1.00 |
| Female | 81 (56) | 1.43 (0.96-2.12) | 191 (62) | 1.45 (1.08-1.94) | 107 (70) | 0.83 (0.54-1.29) | |
| Median age | 66 years | - | 64 years | - | 63 years | - | |
| Age (years) | 18-60 | 55 (38) | 1.00 | 128 (42) | 1.00 | 65 (43) | 1.00 |
| >60 | 90 (62) | 1.37 (0.91-2.07) | 178 (58) | 2.08 (1.55-2.80) | 87 (57) | 2.49 (1.60-3.89) | |
| Age, NCCN-IPI | 18-40 | 4 (3) | 1.00 | 25 (8) | 1.00 | 22 (14) | 1.00 |
| 41-60 | 51 (35) | 0.90 (0.22-3.77) | 103 (34) | 3.13 (1.35-7.25) | 43 (28) | 1.38 (061-3.13) | |
| 61-75 | 64 (44) | 1.24 (0.30-5.10) | 132 (43) | 5.13 (2.25-11.73) | 70 (46) | 2.77 (1.31-5.85) | |
| >75 | 26 (18) | 1.26 (0.29-5.42) | 46 (15) | 6.63 (2.79-15.8) | 17 (11) | 5.12 (2.17-12.1) | |
| WHO PS | 0-1 | 85 (59) | 1.00 | 212 (69) | 1.00 | 107 (70) | 1.00 |
| ≥2 | 60 (41) | 1.66 (1.12-2.45) | 94 (31) | 2.01 (1.51-2.67) | 45 (30) | 3.01 (1.98-4.60) | |
| LDH | normal | 36 (25) | 1.00 | 145 (47) | 1.00 | 76 (50) | 1.00 |
| >ULN | 109 (75) | 1.33 (0.85-2.08) | 161 (53) | 1.96 (1.48-2.60) | 76 (50) | 1.72 (1.14-2.58) | |
| LDH, NCCN-IPI | Normal | 36 (25) | 1.00 | 145 (47) | 1.00 | 76 (50) | 1.00 |
| >1-3× ULN | 103 (71) | 1.31 (0.83-2.05) | 140 (46) | 1.79 (1.33-2.39) | 64 (42) | 1.55 (1.01-2.38) | |
| >3× ULN | 6 (4) | 1.78 (0.62-5.11) | 21 (7) | 4.39 (2.66-7.25) | 12 (8) | 3.21 (1.60-6.41) | |
| Bone Marrow | uninvolved | 76 (52) | 1.00 | 230 (75) | 1.00 | 133 (87) | 1.00 |
| involved | 69 (48) | 1.22 (0.83-1.80) | 76 (25) | 1.65 (1.22-2.23) | 19 (13) | 1.33 (0.74-2.39) | |
| Extranodal involvement (nodes, n) | 0-1 | 124 (86) | 1.00 | 250 (82) | 1.00 | 124 (82) | 1.00 |
| >1 | 21 (14) | 1.55 (0.92-2.61) | 56 (18) | 1.37 (0.97-1.94) | 28 (18) | 1.21 (0.73-2.01) | |
| NCCN-IPI extranodal involvement* | no | 67 (46) | 1.00 | 181 (59) | 1.00 | 110 (72) | 1.00 |
| yes | 78 (54) | 1.30 (0.88-1.92) | 125 (41) | 1.72 (1.30-2.26) | 42 (28) | 1.59 (1.03-2.44) | |
| Stage | I-II | 12 (8) | 1.00 | 68 (22) | 1.00 | 50 (33) | 1.00 |
| Stage | III-IV | 133 (92) | 1.75 (0.77-4.00) | 238 (78) | 2.30 (1.57-3.38) | 102 (67) | 1.86 (1.17-2.94) |
| Prognostic Indices | |||||||
| NCCN-IPI | 0-1 | 2 (1) | 0 (NA) | 23 (15) | 1.00 (reference) | 38 (12) | 1.00 (reference) |
| 2-3 | 35 (24) | 0.51 (0.29-0.88) | 57 (38) | 3.17 (1.56-6.43) | 89 (29) | 2.82 (1.18-6.77) | |
| 4-5 | 77 (53) | 0.59 (0-37-0.94) | 60 (39) | 5.82 (2.94-11.5) | 136 (44) | 5.25 (2.23-12.3) | |
| 6-8 | 31 (21) | 1.00 (reference) | 12 (8) | 10.3 (4.96-21.3) | 43 (14) | 17.2 (6.28-47.2) | |
| c-statistic, OS | 0.591 | 0.664 | 0.688 | ||||
| IPI | 0-1 | 15 (10) | 1.00 (reference) | 53 (35) | 1.00 (reference) | 77 (25) | 1.00 (reference) |
| 2 | 38 (26) | 2.06 (0.89-4.73) | 35 (23) | 2.01 (1.28-3.15) | 76 (25) | 2.35 (1.31-4.23) | |
| 3 | 51 (35) | 2.09 (0.92-4.72) | 35 (23) | 3.15 (2.06-4.81) | 94 (31) | 2.84 (1.59-5.09) | |
| 4-5 | 41 (28) | 3.39 (1.50-7.68) | 29 (19) | 4.61 (2.95-7.21) | 59 (19) | 4.37 (2.40-7.82) | |
| c- statistic, OS | 0.601 | 0.664 | 0.678 | ||||
| PIT | 0 | 9 (6) | 1.00 (reference) | 28 (18) | 1.00 (reference) | 56 (18) | 1.00 (reference) |
| 1 | 34 (23) | 1.17 (0.48-2.89) | 54 (36) | 2.42 (1.42-4.13) | 83 (27) | 2.72 (1.25-5.94) | |
| 2 | 33 (23) | 1.06 (0.43-2.63) | 40 (26) | 3.94 (2.34-6.63) | 91 (30) | 4.70 (2.15-10.27) | |
| 3-4 | 69 (48) | 1.81 (0.78-4.22) | 30 (20) | 5.32 (3.15-9.00) | 76 (25) | 6.93 (3.10-15.5) | |
| c- statistic, OS | 0.591 | 0.66 | 0.689 | ||||
NCCN-IPI extranodal site involvement of bone marrow, central nervous system, lung, liver or gastrointestinal tract.
95% CI, 95% Confidence Interval; AITL, Angioimmunoblastic T-cell lymphoma; ALK- ALCL, anaplastic lymphoma kinase-negative anaplastic large cell lymphoma; HR, Hazard Ratio; IPI, International prognostic index; LDH, lactic dehydrogenase; NCCN, National Comprehensive Cancer Network; OS, Overall Survival; PIT, Prognostic Index for T-cell lymphoma; PS, performance score; PTCL NOS, Peripheral T-cell lymphoma not otherwise specified; ULN, upper limit of normal; WHO, World Health Organization.